Northwest Biotherapeutics, Inc.
NWBO
$0.194
-$0.0134-6.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -28.47% | -23.42% | -12.69% | -38.15% | 14.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.47% | -23.42% | -12.69% | -38.15% | 14.80% |
| Cost of Revenue | 25.81% | 7.40% | 2.55% | -23.28% | -11.12% |
| Gross Profit | -29.88% | -9.73% | -3.57% | 22.37% | 12.60% |
| SG&A Expenses | 11.08% | 6.22% | 2.59% | -5.09% | -10.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.19% | 6.79% | 2.57% | -14.85% | -16.59% |
| Operating Income | -19.82% | -7.87% | -3.05% | 14.10% | 17.38% |
| Income Before Tax | -33.83% | 9.60% | 14.57% | 30.76% | 40.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.83% | 9.60% | 14.57% | 30.76% | 40.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.83% | 9.60% | 14.57% | 30.76% | 40.40% |
| EBIT | -19.82% | -7.87% | -3.05% | 14.10% | 17.38% |
| EBITDA | -19.97% | -7.52% | -2.45% | 14.62% | 18.12% |
| EPS Basic | -18.99% | 17.85% | 21.32% | 35.85% | 44.11% |
| Normalized Basic EPS | -21.10% | 12.43% | 27.92% | 42.05% | 50.80% |
| EPS Diluted | -42.51% | -0.98% | 10.35% | 31.67% | 44.11% |
| Normalized Diluted EPS | -21.10% | 12.43% | 27.92% | 42.05% | 50.80% |
| Average Basic Shares Outstanding | 11.00% | 10.13% | 9.64% | 9.84% | 10.18% |
| Average Diluted Shares Outstanding | 11.00% | 10.13% | 9.64% | 9.84% | 10.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
